5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control

Yousefzadeh, F. and Sahebolzamani, E. and Sadri, A. and Mortezaei, A. and Aqamolaei, A. and Mortazavi, S.H. and Shalbafan, M.R. and Ghaffari, S. and Alikhani, R. and Mousavi, S.B. and Naderi, S. and Shamabadi, A. and Jalilevand, S. and Akhondzadeh, S. (2020) 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. International Clinical Psychopharmacology, 35 (5). pp. 254-262.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytryptophan in treating OCD was the aim of the present randomized, double-blind, placebo-controlled 12-week trial. In a 12-week, randomized double-blind study, 60 patients with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of moderate to severe OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >21 were randomly assigned to receive either fluoxetine plus placebo or fluoxetine plus 5-hydroxytryptophan (100 mg twice daily). All patients, regardless of their treatment group, received fluoxetine at 20 mg/day for the initial 4 weeks of the study followed by 60 mg/day of fluoxetine for the rest of the trial course. Symptoms were assessed using the Y-BOCS at baseline and weeks 4, 8 and 12. General linear model repeated measure showed significant effects for time � treatment interaction on total Y-BOCS (F = 12.07, df = 2.29, P-value <0.001), obsession (F = 8.25, df = 1.91, P-value = 0.001) and compulsion subscale scores (F = 6.64, df = 2.01, P-value = 0.002). 5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores. The results of this study confirm that 5-hydroxytryptophan may be effective as an augmentative agent in treatment of moderate-to-severe OCD. © 2020 Lippincott Williams and Wilkins. All rights reserved.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: 5 hydroxytryptophan; fluoxetine; placebo, abdominal pain; adjuvant therapy; adult; Article; clinical effectiveness; clinical outcome; constipation; controlled study; diarrhea; disease severity; dizziness; double blind procedure; drug efficacy; drug safety; DSM-5; fatigue; female; human; major clinical study; male; nausea; nervousness; obsession; obsessive compulsive disorder; parallel design; priority journal; randomized controlled trial; rash; side effect; tachycardia; treatment duration; treatment response; vomiting; xerostomia; Yale Brown Obsessive Compulsive Scale
Subjects: WM Psychiatry
Depositing User: eprints admin
Date Deposited: 30 May 2021 05:00
Last Modified: 01 Jun 2021 04:22
URI: http://eprints.iums.ac.ir/id/eprint/34177

Actions (login required)

View Item View Item